drugset / Trial / NCT00177281
Safety Study of S-CKD602 in Patients With Advanced Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to evaluate a new anti-cancer drug called S CKD602, developed by ALZA Corporation. The drug is investigational and not approved by the Food and Drug administration (FDA). The side effects (the way the drug acts in your body) and the effect it has on your disease will be studied.
Timeline
- Start
- 2003-09
- Primary completion
- 2006-05
- Completion
- 2006-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | S CKD602 | Unknown | — | — |